p16阳性非口咽黏膜头颈癌的疾病部位特异性结局
本研究回顾性分析2009—2021年接受根治性治疗的3061例非口咽头颈鳞癌,比较p16阳性、阴性与未检测者的无病生存(DFS)。p16阳性者5年DFS优于p16阴性/未检测者(74% vs 48%/59%),获益见于喉、下咽、鼻腔,但鼻窦与口腔未见显著差异。
要点
- p16阳性非口咽头颈鳞癌整体DFS显著优于p16阴性/未检测者。
- 喉、下咽、鼻腔p16阳性者DFS获益显著,鼻窦与口腔无显著差异。
- p16状态应结合疾病部位解读,不同部位预后意义不同。
核心结论
- p16阳性在喉、下咽、鼻腔鳞癌中与DFS获益相关,但在鼻窦或口腔鳞癌中未见显著DFS差异。
研究设计与样本
- 回顾性队列研究,纳入2009—2021年接受根治性治疗的非口咽头颈鳞癌3061例,其中p16阳性91例、p16阴性375例、未检测2595例,中位随访4.7年。
主要发现
- p16阳性者5年DFS为74%,优于p16阴性者的48%和未检测者的59%(aHR 0.40 [0.26-0.61],p < 0.001)。
- 喉癌中p16阳性者5年DFS为86%,优于p16阴性/未检测者的52%/63%(aHR 0.26 [0.09-0.71],p = 0.005)。
- 下咽癌中p16阳性者5年DFS为70%,优于p16阴性/未检测者的25%/37%(aHR 0.55 [0.10-0.50],p < 0.001)。
- 鼻腔癌中p16阳性者5年DFS为82%,优于p16阴性/未检测者的38%/66%(aHR 0.31 [0.11-0.88],p = 0.028)。
- 鼻窦癌(40% vs 64%/41%,p = 0.39)与口腔癌(50% vs 57%/58%,p = 0.94)中未见显著DFS差异。
临床怎么用
- 对喉、下咽、鼻腔非口咽头颈鳞癌可检测p16,辅助判断DFS预后。
- 鼻窦与口腔鳞癌的p16状态不宜直接用于DFS预后分层。
局限性
- p16阳性样本量较小(91例),部分亚组事件数有限。
- 为回顾性研究,p16未检测者占多数(2595例),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report disease-free survival (DFS) in p16-positive non-oropharyngeal head-and-neck squamous-cell carcinoma (HNSCC). METHODS: Curatively-treated non-oropharyngeal HNSCC (2009-2021) were reviewed. DFS was compared among p16-positive, p16-negative, and p16-untested cases for the overall cohort and by disease site. Multivariable analysis estimated adjusted hazard ratio (aHR) for p16-positivity. RESULTS: Among 3061 non-oropharyngeal HNSCC, 91 p16+, 375 p16-, 2595 untested; median follow-up 4.7 years. P16-positive patients had superior 5-year DFS versus p16-/untested (74% vs. 48%/59%; aHR 0.40 [0.26-0.61], p < 0.001). This advantage was evident in the larynx (86% vs. 52%/63%; aHR 0.26 [0.09-0.71], p = 0.005), hypopharynx (70% vs. 25%/37%; aHR 0.55 [0.10-0.50], p < 0.001), and nasal cavity (82% vs. 38%/66%; aHR 0.31 [0.11-0.88], p = 0.028). No significant DFS differences were seen in paranasal sinus (40% vs. 64%/41%; p = 0.39) or oral cavity (50% vs. 57%/58%; p = 0.94). CONCLUSION: p16-positivity confers a DFS benefit in larynx/hypopharynx/nasal cavity, but not in paranasal sinus or oral SCC.
引用
- Chelvarajah RC, Chee LYS, Su J, et al. Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer. Head Neck. 2026. PMID: 41816946. doi:10.1002/hed.70230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。